The carpet in the main hall of the Business Design Centre in Islington was worn thin by the time the final panel wrapped on 14 May 2026. Cannabis Europa London — the flagship annual gathering for European cannabis professionals — had drawn over 1,200 delegates from 34 countries. But this year, the mood was impatience. The conference, held against the backdrop of the UK’s painfully slow medical programme and the EU’s accelerating regulatory engine, felt less like a trade show and more like a two-day therapy session for an industry caught between hope and inertia.
EU Momentum vs. British Isolation
The dominant theme of the event was regulatory divergence. On the first morning, a panel titled ‘Harmonisation or Fragmentation?’ laid out the numbers: Germany’s medical cannabis reimbursements hit a record €78 million in Q1 2026, up 42% year-on-year. The German Cannabis Agency (BfArM) has now licensed 12 new domestic cultivation sites, with the first harvest of the 2026 cycle expected in August. Meanwhile, the European Commission’s Directorate-General for Health has published a draft framework for cross-border medical cannabis prescriptions — a move that, if adopted in late 2026, would allow a patient in France to fill a prescription at a pharmacy in Spain without duplicative paperwork.
In contrast, the UK’s presentation was a study in frustration. Dr. Sarah Lansbury, a consultant psychiatrist at the Royal London Hospital, noted that fewer than 3,000 NHS prescriptions for cannabis-based products have been issued since 2018, and that the private market — estimated at just over £45 million in 2025 — remains prohibitively expensive for most patients. “We are watching our neighbours build a continental network whilst we argue about which conditions qualify for a single specialist opinion,” she said, to a smattering of applause. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has not approved a single new cannabis-based medicine since Sativex in 2010.
Investment Shifts East and the Adult-Use Wave
Investment trends were another flashpoint. The flow of capital has unmistakably shifted from North America and the UK toward mainland Europe. According to data presented by Prohibition Partners on day two, European cannabis companies raised €420 million in equity and debt in the first four months of 2026 — a 35% increase over the same period in 2025. The largest single round was a €60 million Series B for Prague-based LEXA Medical, which is building a GMP-certified extraction facility in the Czech Republic. The company’s CEO, Jan Novák, confirmed that his firm is preparing for the country’s planned adult-use pilot programme, expected to launch in January 2027.
The adult-use conversation at Cannabis Europa was no longer theoretical. A dedicated track on ‘Beyond Medical’ featured representatives from the Czech Republic, the Netherlands, and Malta. The Dutch government confirmed that its regulated closed coffee shop supply chain pilot — operating in ten municipalities — had already processed over 1,200 kilograms of flower in its first six months, with zero diversion to the illicit market. The Czech delegation announced that its Chamber of Deputies had passed the first reading of a bill to legalise adult-use sales for adults over 21, with a regulated market to be overseen by a new State Agency for Cannabis. The target date: April 2027. As one delegate put it during the closing keynote: “The question is no longer whether Europe will have adult-use markets. The question is whether the UK will be left behind.”
For now, the answer appears to be yes. As the delegates filed out into the May sunshine, clutching tote bags and business cards, the centre of gravity in European cannabis has moved decisively to the east and north. The UK, once the pioneer of global cannabis reform, is now a cautionary tale of what happens when policy fails to keep pace with patient need and economic opportunity.
